Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01CIB
|
|||
| Former ID |
DNCL002970
|
|||
| Drug Name |
SAR164653
|
|||
| Indication | Diabetic complication [ICD-11: 5A2Y; ICD-10: E08-E13] | Phase 1 | [1] | |
| Company |
Sanofi
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cathepsin A (CTSA) | Target Info | Modulator | [2] |
| KEGG Pathway | Lysosome | |||
| Renin-angiotensin system | ||||
| Reactome | Glycosphingolipid metabolism | |||
| MHC class II antigen presentation | ||||
| Sialic acid metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035270) | |||
| REF 2 | Tolerability, safety and pharmacokinetics of the novel Cathepsin A inhibitor SAR164653 in healthy subjects.Clinical Pharmacology in Drug Development 05/2015. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.